NINCDS-ADRDA Criteria for Alzheimer’s Disease
Why Use
Provides a standardized framework for diagnosing possible or probable AD in both clinical and research settings.
When to Use
Use when evaluating patients with cognitive impairment suspected to be due to Alzheimer disease (AD).
Formula
Pearls / Pitfalls
Developed in 1984, these criteria were a key tool for diagnosing AD but were revised in 2011 to form the National Institute on Aging and Alzheimer Association (NIA-AA) criteria . They predate advances in AD research and do not incorporate modern diagnostic tools, such as CSF biomarkers or amyloid PET imaging. Diagnosis requires ruling out other potential causes, including vascular dementia, medications, and psychiatric conditions.
Advice
Always exclude reversible causes of cognitive decline (e.g., vitamin B12 deficiency, hypothyroidism, structural brain pathology). Consider supplementing these criteria with modern diagnostic tools. If the criteria support an AD diagnosis, consider: Tailoring treatment based on disease stage and symptom severity, considering cholinesterase inhibitors, memantine, or newly available therapies as appropriate. Reinforcing non-pharmacologic interventions (e.g., exercise, cognitive training, social engagement). Offering caregiver support resources and discussing advanced care planning. Monitoring disease progression and reassessing treatment plans periodically. For complex cases or those requiring advanced imaging or biomarkers, consider referral to neurology or geriatric psychiatry.
More Information
Interpretation: Clinical diagnosis for AD Rate of AD by pathological diagnosis Probable AD 91% Possible AD 92% The sensitivity and specificity of a clinical diagnosis of Probable AD or Possible AD for a pathological diagnosis of AD are 83% and 84%, respectively ( Blacker 1994 ).